What to Expect From Pfizer's Non-Oncology Business in Q4?

Pfizer will report fourth-quarter and full-year 2025 results on Feb. 3, with oncology representing more than 28% of revenues and investor focus on cancer franchises and non-oncology drivers; Zacks projects Eliquis alliance revenues of $2.1B, Prevnar family sales of $1.64B and Vyndaqel family sales of $1.66B. The preview flags declines in Comirnaty and Paxlovid revenue due to narrowed U.S. COVID recommendations and lower infections, weaker U.S. Prevnar and limited U.S. uptake of Abrysvo, partially offset by international vaccine gains and stronger Nurtec and Vyndaqel demand. Despite an inexpensive valuation (8.58x forward P/E vs. 17.73 for the industry), Zacks cut 2026 EPS from $3.14 to $3.00 over 60 days and assigns a Rank #4 (Sell), suggesting a cautious near-term outlook for the stock.

Analysis

Market structure: Pfizer’s mix shift (oncology >28% of revenue) means downticks in vaccines/COVID/Paxlovid compress top-line but core oncology and recently acquired ADCs provide pricing power versus generics; expect winners = diversified large-cap pharmas with oncology exposure (Pfizer, BMY indirectly) and losers = narrow COVID/RSV plays and ex‑US generic entrants. Lower Paxlovid/Comirnaty demand signals durable downshift in pandemic-driven vaccine tail; short-term demand shock favors margin-stable drugs (Vyndaqel, Ibrance) and international vaccine markets where growth persists.

Risk assessment: Near-term catalyst risk centers on Feb 3 Q4 print and ACIP guidance (next 30–60 days); Zacks cut to $3.00/sh (−4.5% in 60 days) shows modest downward revisions but not collapse. Tail risks: adverse ACIP rulings, major patent loss on alliance products, or an unexpected safety recall could knock >15–25% equity value; long-term upside depends on successful ADC integration and 12–36 month commercial execution.

Trade implications: Tactical conviction: valuation (forward P/E 8.6 vs industry 17.7) supports sized long with hedges. Recommended instruments: equity longs with protective puts or a relative-value long PFE / short BNTX pair to express diversified pharma vs vaccine-exposed biotech over 3–6 months. Expect IV to rise 20–40% into earnings — use options to shape risk/reward.

Contrarian angle: Market appears to underprice steady alliance streams (Eliquis ~$2.1bn est) and oncology resilience; if oncology sales beat by >5–7% sequentially, re-rating is likely. The consensus may overreact to transitory vaccine normalization; historical post‑pandemic pharma re‑ratings (2022–23) show durable rebounds when pipeline and cash generation remain intact.

Key Decisions for Investors

• Establish a 2–3% long position in PFE (stock) within 5 business days and hedge with a 3‑week 10% OTM put (expiry ~Feb 21) allocating 0.4–0.6% notional to the put; rationale: cheap forward P/E and limited downside ahead of Feb 3 earnings.
• Put on a relative-value trade: long PFE 2% vs short BNTX 1.5% (dollar‑neutral) for a 3–6 month horizon; unwind/trim if Comirnaty revenue guidance surprises by >±15% or if PFE oncology sales miss/beat by >7%.
• If implied volatility on PFE front‑month options <35% before Feb 3, buy an ATM straddle sized to 0.5–1% portfolio risk to capture an earnings move; if IV >35%, instead sell a 25–35 delta iron condor for premium (defined-risk).
• Reduce direct exposure to pure vaccine/reliant biotechs (e.g., reduce BNTX exposure by up to 30%) if Q4 Comirnaty/Paxlovid sales miss consensus by >20% or ACIP issues further restrictive guidance within 60 days.